MTHFR Allele and One-Carbon Metabolic Profile Predict Severity of COVID-19 Disease 2260350

C Caitlin Syphurs (Precision Vaccines Program, Boston Children’s Hospital) B Boryana Petrova A Andrew Culhane (Boston Children’s Hospital) J Jing Chen E Ernie Chen (Department of Neurology, Yale School of Medicine) R Ruth Montgomery (Yale School of Medicine) S Steven Kleinstein (Yale University School of Medicine) K Kinga Smolen (Boston Children’s Hospital/Harvard Medical School) K Kevin Mendez (Harvard Medical School) J Jessica Lasky Su (Brigham andWomen’s Hospital, Boston, MA, USA.) H Hanno Steen (Department of Pathology, Boston Children’s Hospital) O Ofer Levy (Harvard Medical School) J Joann Diray-Arce (Harvard Medical School) N Naama Kanarek

Abstract

Abstract Introduction Alterations in the methionine cycle, a key component of the one-carbon metabolism pathway that is critical for viral propagation and disease progression, may serve as early indicators of severe SARS-CoV-2 infection. Methods As part of the Immunophenotyping Assessment in a COVID-19 Cohort (IMPACC) study, we performed a longitudinal analysis of untargeted plasma metabolic profiles of hospitalized adult COVID-19 patients followed from admission to 1-year post-discharge. Using a 7-point ordinal scale, patients were clustered into 5 disease trajectory groups based on respiratory illness during hospitalization and targeted metabolomics was assessed using liquid chromatography-mass spectrometry. Results Metabolic profiling revealed that patients in more severe disease trajectory groups (TG4-TG5) showed alterations in the methionine cycle. Specifically, S-adenosylmethionine (SAM), a methyl group donor important for gene expression and methylation of DNA, RNA and proteins, was highly abundant among the more severe trajectory groups (TG4-TG5) compared to the less severe trajectory groups (TG1-TG3). In addition, we identified the C766T allele mutation of the MTHFR gene, a common polymorphism, as a genetic contributor to the methionine pathway and predictor of disease trajectory. Conclusion These results highlight the potential of metabolic characterization of the methionine pathway in combination with screening for the common genetic MTHFR variant as a practical approach for precision COVID-19 management. Funding Source NIH (3U01AI167892-03S2, 3U01AI167892-01S2, 5R01AI135803-03, 5U19AI118608-04, 5U19AI128910-04, 4U19AI090023-11, 4U19AI118610-06, R01AI145835-01A1S1, 5U19AI062629-17, 5U19AI057229-17, 5U19AI057229-18, 5U19AI125357-05, 5U19AI128913-03, 3U19AI077439-13, 5U54AI142766-03, 5R01AI104870-07, 3U19AI089992-09, and 5T32DA018926-18, 3U19AI1289130, U19AI128913-04S1, and R01AI122220, UM1TR004528); NSF DMS2310836 Topic Categories Computational and Systems Immunology (COMP)

Article Details

Volume / Issue Vol. 215, Issue Supplement_1
Published August 01, 2026
ISSN 0022-1767
Publisher American Association of Immunologists

Authors (14)

C

Caitlin Syphurs

Precision Vaccines Program, Boston Children’s Hospital

B

Boryana Petrova

A

Andrew Culhane

Boston Children’s Hospital

J

Jing Chen

E

Ernie Chen

Department of Neurology, Yale School of Medicine

R

Ruth Montgomery

Yale School of Medicine

S

Steven Kleinstein

Yale University School of Medicine

K

Kinga Smolen

Boston Children’s Hospital/Harvard Medical School

K

Kevin Mendez

Harvard Medical School

J

Jessica Lasky Su

Brigham andWomen’s Hospital, Boston, MA, USA.

H

Hanno Steen

Department of Pathology, Boston Children’s Hospital

O

Ofer Levy

Harvard Medical School

J

Joann Diray-Arce

Harvard Medical School

N

Naama Kanarek